HemaSphere Journal
@hemasphere-journal.bsky.social
The official open access journal of EHA - we publish basic, translational, & clinical heme research. 2024 stats: #ImpactFactor = 14.6 (ranked #5).
#hematology #ScientificPublishing #BloodSky #HemeSky
👓 hemaspherejournal.com
#hematology #ScientificPublishing #BloodSky #HemeSky
👓 hemaspherejournal.com
This recently published paper reports that isatuximab plus chemotherapy showed initial efficacy in children with relapsed acute leukemia, but complete response rates did not meet criteria for further study. Toxicity was manageable👉https://bit.ly/4qyzM8l
#Pediatric #Hematology
#Pediatric #Hematology
November 17, 2025 at 9:02 AM
This recently published paper reports that isatuximab plus chemotherapy showed initial efficacy in children with relapsed acute leukemia, but complete response rates did not meet criteria for further study. Toxicity was manageable👉https://bit.ly/4qyzM8l
#Pediatric #Hematology
#Pediatric #Hematology
Replay!
Scientific Editor Dr Charles de Bock hosts Dr Thomas Mercher & Dr Alexandre Fagnan in this episode highlighting ETO2 activated gene transcription and how this affects erythroleukemia.
This episode is on our website and all major podcast platforms 🎧 https://bit.ly/3WNmEyA
Scientific Editor Dr Charles de Bock hosts Dr Thomas Mercher & Dr Alexandre Fagnan in this episode highlighting ETO2 activated gene transcription and how this affects erythroleukemia.
This episode is on our website and all major podcast platforms 🎧 https://bit.ly/3WNmEyA
November 14, 2025 at 3:13 PM
Replay!
Scientific Editor Dr Charles de Bock hosts Dr Thomas Mercher & Dr Alexandre Fagnan in this episode highlighting ETO2 activated gene transcription and how this affects erythroleukemia.
This episode is on our website and all major podcast platforms 🎧 https://bit.ly/3WNmEyA
Scientific Editor Dr Charles de Bock hosts Dr Thomas Mercher & Dr Alexandre Fagnan in this episode highlighting ETO2 activated gene transcription and how this affects erythroleukemia.
This episode is on our website and all major podcast platforms 🎧 https://bit.ly/3WNmEyA
📰Explore the newly released #EHAGuidelines for mantle cell lymphoma (#MCL) in HemaSphere. Developed by leading experts, these guidelines offer insight into treatment approaches, emerging non-chemo combinations, and innovations in relapsed/refractory care 👉https://bit.ly/47gdpLV
November 13, 2025 at 11:32 AM
📰Explore the newly released #EHAGuidelines for mantle cell lymphoma (#MCL) in HemaSphere. Developed by leading experts, these guidelines offer insight into treatment approaches, emerging non-chemo combinations, and innovations in relapsed/refractory care 👉https://bit.ly/47gdpLV
HemaTopics are HemaSphere publications focusing on 🔥 hematology topics. This week we focus on the latest HemaTopic by Scientific Editor L Merz, discussing the updated #CTCAE v6 & how the changes better reflect genetic diversity, such as the Duffy null variant 👉https://bit.ly/3LbIetU
November 12, 2025 at 10:02 AM
HemaTopics are HemaSphere publications focusing on 🔥 hematology topics. This week we focus on the latest HemaTopic by Scientific Editor L Merz, discussing the updated #CTCAE v6 & how the changes better reflect genetic diversity, such as the Duffy null variant 👉https://bit.ly/3LbIetU
🔬 This Comment to a recent HemaSphere paper highlights that the ELN Scoring System shows high sensitivity & specificity in diagnosing #MDS and #CMML, validated across large cohorts. 👉https://bit.ly/4nzRB4U
Original article 📰https://bit.ly/4kVm8cv
Original article 📰https://bit.ly/4kVm8cv
November 11, 2025 at 4:02 PM
🔬 This Comment to a recent HemaSphere paper highlights that the ELN Scoring System shows high sensitivity & specificity in diagnosing #MDS and #CMML, validated across large cohorts. 👉https://bit.ly/4nzRB4U
Original article 📰https://bit.ly/4kVm8cv
Original article 📰https://bit.ly/4kVm8cv
This recent article reports that combining venetoclax with full-dose CPX-351 led to high remission rates and enabled most newly diagnosed AML patients, even those with high-risk features, to proceed to stem cell transplant safely.
Read more in our October issue 📖 https://bit.ly/3IV6zDK
Read more in our October issue 📖 https://bit.ly/3IV6zDK
November 10, 2025 at 12:02 PM
This recent article reports that combining venetoclax with full-dose CPX-351 led to high remission rates and enabled most newly diagnosed AML patients, even those with high-risk features, to proceed to stem cell transplant safely.
Read more in our October issue 📖 https://bit.ly/3IV6zDK
Read more in our October issue 📖 https://bit.ly/3IV6zDK
🔬 New Podcast!
Dr Anikó Sijs-Szabó & Roger Mulet Lázaro PhD join Dr. Charles de Bock to unpack the challenges of diagnosing & treating acute leukemias of ambiguous lineage #ALAL.
🎧 Listen now on all major platforms & read the full open-access article https://bit.ly/4oeJo6w
#Hematology
Dr Anikó Sijs-Szabó & Roger Mulet Lázaro PhD join Dr. Charles de Bock to unpack the challenges of diagnosing & treating acute leukemias of ambiguous lineage #ALAL.
🎧 Listen now on all major platforms & read the full open-access article https://bit.ly/4oeJo6w
#Hematology
November 7, 2025 at 10:02 AM
🔬 New Podcast!
Dr Anikó Sijs-Szabó & Roger Mulet Lázaro PhD join Dr. Charles de Bock to unpack the challenges of diagnosing & treating acute leukemias of ambiguous lineage #ALAL.
🎧 Listen now on all major platforms & read the full open-access article https://bit.ly/4oeJo6w
#Hematology
Dr Anikó Sijs-Szabó & Roger Mulet Lázaro PhD join Dr. Charles de Bock to unpack the challenges of diagnosing & treating acute leukemias of ambiguous lineage #ALAL.
🎧 Listen now on all major platforms & read the full open-access article https://bit.ly/4oeJo6w
#Hematology
This recent paper shows about 10% of recent hematology trials use eligibility criteria that may exclude people with the Duffy null variant. The authors recommend adjusting trial designs to ensure fair inclusion of all patient groups.
Read more in depth here 👉https://bit.ly/4qemD4j
Read more in depth here 👉https://bit.ly/4qemD4j
November 6, 2025 at 5:05 PM
This recent paper shows about 10% of recent hematology trials use eligibility criteria that may exclude people with the Duffy null variant. The authors recommend adjusting trial designs to ensure fair inclusion of all patient groups.
Read more in depth here 👉https://bit.ly/4qemD4j
Read more in depth here 👉https://bit.ly/4qemD4j
📢 The November issue is now open!
Opening the issue: Integrating transcriptomic profiling & machine learning for a clinically actionable prognostic model in infant AML.
Read now 👉 https://bit.ly/43SOq0i
#AML #MachineLearning #Transcriptomics
Opening the issue: Integrating transcriptomic profiling & machine learning for a clinically actionable prognostic model in infant AML.
Read now 👉 https://bit.ly/43SOq0i
#AML #MachineLearning #Transcriptomics
November 6, 2025 at 11:03 AM
📢 The November issue is now open!
Opening the issue: Integrating transcriptomic profiling & machine learning for a clinically actionable prognostic model in infant AML.
Read now 👉 https://bit.ly/43SOq0i
#AML #MachineLearning #Transcriptomics
Opening the issue: Integrating transcriptomic profiling & machine learning for a clinically actionable prognostic model in infant AML.
Read now 👉 https://bit.ly/43SOq0i
#AML #MachineLearning #Transcriptomics
🩸 Fresh in HemaSphere Vol. 9(10): B-cell regulation in #WM, ISAKIDS trial, #CAR T-cell therapy burden, ALDH1 in AML, NGS in myeloma, HTLV-1 awareness, & more. Explore cutting-edge hematology!
📰https://bit.ly/4qOjoRm
#HemaSphere #BloodCancer #Hematology
📰https://bit.ly/4qOjoRm
#HemaSphere #BloodCancer #Hematology
November 5, 2025 at 11:03 AM
🩸 Fresh in HemaSphere Vol. 9(10): B-cell regulation in #WM, ISAKIDS trial, #CAR T-cell therapy burden, ALDH1 in AML, NGS in myeloma, HTLV-1 awareness, & more. Explore cutting-edge hematology!
📰https://bit.ly/4qOjoRm
#HemaSphere #BloodCancer #Hematology
📰https://bit.ly/4qOjoRm
#HemaSphere #BloodCancer #Hematology
HTLV-1 is a silent but serious public health threat in Africa; millions are infected, yet most remain undiagnosed due to limited testing and awareness. Urgent action is needed: improved screening, education, and policy can save lives and stop the spread.
👉https://bit.ly/4qI00oW
👉https://bit.ly/4qI00oW
November 4, 2025 at 4:03 PM
HTLV-1 is a silent but serious public health threat in Africa; millions are infected, yet most remain undiagnosed due to limited testing and awareness. Urgent action is needed: improved screening, education, and policy can save lives and stop the spread.
👉https://bit.ly/4qI00oW
👉https://bit.ly/4qI00oW
This paper shows that ex vivo drug response profiling, combined with molecular analysis, can predict relapse risk and reveal resistance mechanisms in pediatric BCP-ALL, highlighting new targets for precision medicine.
Read more here 👉https://bit.ly/3GYLozA
#pediatric #hematology
Read more here 👉https://bit.ly/3GYLozA
#pediatric #hematology
November 3, 2025 at 4:04 PM
This paper shows that ex vivo drug response profiling, combined with molecular analysis, can predict relapse risk and reveal resistance mechanisms in pediatric BCP-ALL, highlighting new targets for precision medicine.
Read more here 👉https://bit.ly/3GYLozA
#pediatric #hematology
Read more here 👉https://bit.ly/3GYLozA
#pediatric #hematology
Explore the latest research lurking in our October issue… if you dare! 🎃👻🧟♀️http://bit.ly/4haMwh3
October 31, 2025 at 1:44 PM
Explore the latest research lurking in our October issue… if you dare! 🎃👻🧟♀️http://bit.ly/4haMwh3
Sneak peek of the next podcast episode!
Host Dr Charles de Bock chats with Aniko Sijs-Szabo and Roger Mulet-Lázaro, co-authors of "Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B-ALL or T-ALL"
Host Dr Charles de Bock chats with Aniko Sijs-Szabo and Roger Mulet-Lázaro, co-authors of "Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B-ALL or T-ALL"
October 30, 2025 at 10:04 AM
Sneak peek of the next podcast episode!
Host Dr Charles de Bock chats with Aniko Sijs-Szabo and Roger Mulet-Lázaro, co-authors of "Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B-ALL or T-ALL"
Host Dr Charles de Bock chats with Aniko Sijs-Szabo and Roger Mulet-Lázaro, co-authors of "Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B-ALL or T-ALL"
This paper shows that circulating tumor cell counts in newly diagnosed multiple myeloma #MM reflect aggressive disease biology and outperform current transcriptomic markers. The authors suggest integrating CTC data could improve risk stratification and clinical decision-making👉https://bit.ly/4mytPot
October 29, 2025 at 10:01 AM
This paper shows that circulating tumor cell counts in newly diagnosed multiple myeloma #MM reflect aggressive disease biology and outperform current transcriptomic markers. The authors suggest integrating CTC data could improve risk stratification and clinical decision-making👉https://bit.ly/4mytPot
Authors show that after initial chemotherapy in pediatric AML, T-cell levels in bone marrow often increase or remain stable, suggesting a possible window for T-cell engager therapy, They highlight the need for further research on timing and immune recovery.
👉https://bit.ly/3ImTDGg
👉https://bit.ly/3ImTDGg
October 28, 2025 at 10:01 AM
Authors show that after initial chemotherapy in pediatric AML, T-cell levels in bone marrow often increase or remain stable, suggesting a possible window for T-cell engager therapy, They highlight the need for further research on timing and immune recovery.
👉https://bit.ly/3ImTDGg
👉https://bit.ly/3ImTDGg
This recently published paper shows that the female predominance in #PMBCL is linked to Xq24/IL13RA1 defects. Authors found that unique genetic and epigenetic mechanisms in women drive these changes, which activate oncogenic pathways and define the disease. 👉https://bit.ly/3VI2ohd
October 27, 2025 at 10:01 AM
This recently published paper shows that the female predominance in #PMBCL is linked to Xq24/IL13RA1 defects. Authors found that unique genetic and epigenetic mechanisms in women drive these changes, which activate oncogenic pathways and define the disease. 👉https://bit.ly/3VI2ohd
🚨REPLAY🚨
In this 2nd part of a 2-part episode, Dr Charles De Bock engages with Prof Dr Petya Apostolova and Dr Jörg Büscher to explore the intricate relationship between metabolism and hematology ➡️https://bit.ly/4o5oE1s
Find the referenced Review in full & open access: https://bit.ly/4kiYh5w
In this 2nd part of a 2-part episode, Dr Charles De Bock engages with Prof Dr Petya Apostolova and Dr Jörg Büscher to explore the intricate relationship between metabolism and hematology ➡️https://bit.ly/4o5oE1s
Find the referenced Review in full & open access: https://bit.ly/4kiYh5w
October 24, 2025 at 10:58 AM
🚨REPLAY🚨
In this 2nd part of a 2-part episode, Dr Charles De Bock engages with Prof Dr Petya Apostolova and Dr Jörg Büscher to explore the intricate relationship between metabolism and hematology ➡️https://bit.ly/4o5oE1s
Find the referenced Review in full & open access: https://bit.ly/4kiYh5w
In this 2nd part of a 2-part episode, Dr Charles De Bock engages with Prof Dr Petya Apostolova and Dr Jörg Büscher to explore the intricate relationship between metabolism and hematology ➡️https://bit.ly/4o5oE1s
Find the referenced Review in full & open access: https://bit.ly/4kiYh5w
This Editorial highlights the need to expand hospital exemption for #ATMPs. Authors emphasize the importance of public SoHO establishments in advancing access, affordability, and quality of cell-based therapies, urging policymakers to strengthen regulatory frameworks 👉https://bit.ly/4mwg3Tk
October 23, 2025 at 9:30 AM
This Editorial highlights the need to expand hospital exemption for #ATMPs. Authors emphasize the importance of public SoHO establishments in advancing access, affordability, and quality of cell-based therapies, urging policymakers to strengthen regulatory frameworks 👉https://bit.ly/4mwg3Tk
Patient-centered and proportionate safety reporting in clinical trials is an EHA priority. Learn more about EHA's work in this recent HemaSphere Perspective: https://bit.ly/3JbBL1s
October 22, 2025 at 2:06 PM
Patient-centered and proportionate safety reporting in clinical trials is an EHA priority. Learn more about EHA's work in this recent HemaSphere Perspective: https://bit.ly/3JbBL1s
#CNS relapse is a concern in high CNS IPI #DLBCL, with CNS prophylaxis considered, though likely ineffective. Systemic relapse is more common and a major cause of death, and authors suggest a focus on systemic treatment., account=@MarekTrnenyDr.
👉https://bit.ly/3JYhiNF
👉https://bit.ly/3JYhiNF
October 22, 2025 at 9:31 AM
#CNS relapse is a concern in high CNS IPI #DLBCL, with CNS prophylaxis considered, though likely ineffective. Systemic relapse is more common and a major cause of death, and authors suggest a focus on systemic treatment., account=@MarekTrnenyDr.
👉https://bit.ly/3JYhiNF
👉https://bit.ly/3JYhiNF
Burnout is highly prevalent among hematology professionals, and it is primarily driven by modifiable structural factors. Time to move ahead ! 🚨https://bit.ly/3IDNJR4
October 21, 2025 at 5:02 PM
Burnout is highly prevalent among hematology professionals, and it is primarily driven by modifiable structural factors. Time to move ahead ! 🚨https://bit.ly/3IDNJR4
📚 Never stop learning with HemaSphere Journal! Access high-quality hematology publications, always #OpenAccess.
Our current issue in progress can always be found here 👉https://bit.ly/3GIlBvj
#OpenAccess #MedicalEducation #CareerDevelopment
Our current issue in progress can always be found here 👉https://bit.ly/3GIlBvj
#OpenAccess #MedicalEducation #CareerDevelopment
HemaSphere: Vol 9, No 10
Click on the title to browse this issue
bit.ly
October 21, 2025 at 9:01 AM
📚 Never stop learning with HemaSphere Journal! Access high-quality hematology publications, always #OpenAccess.
Our current issue in progress can always be found here 👉https://bit.ly/3GIlBvj
#OpenAccess #MedicalEducation #CareerDevelopment
Our current issue in progress can always be found here 👉https://bit.ly/3GIlBvj
#OpenAccess #MedicalEducation #CareerDevelopment
Authors report that patients with advanced myeloproliferative neoplasms had poor overall survival. They also found that combining azacitadine with ruxolitinib may improve outcomes, especially in those without complex TP53 multations.
👉https://bit.ly/480KLjS
👉https://bit.ly/480KLjS
October 20, 2025 at 9:04 AM
Authors report that patients with advanced myeloproliferative neoplasms had poor overall survival. They also found that combining azacitadine with ruxolitinib may improve outcomes, especially in those without complex TP53 multations.
👉https://bit.ly/480KLjS
👉https://bit.ly/480KLjS
🎙️PODCAST REPLAY
Host Dr Charles de Bock w/ guests Dr Jörg Büscher & Prof Dr Petya Apostolova discuss the critical role of metabolism in cellular function, particularly in the context of hematology & cancer research.
All major podcast platforms 🎧 https://bit.ly/4kiYh5w 📺https://bit.ly/46XCQBY
Host Dr Charles de Bock w/ guests Dr Jörg Büscher & Prof Dr Petya Apostolova discuss the critical role of metabolism in cellular function, particularly in the context of hematology & cancer research.
All major podcast platforms 🎧 https://bit.ly/4kiYh5w 📺https://bit.ly/46XCQBY
October 17, 2025 at 10:51 AM
🎙️PODCAST REPLAY
Host Dr Charles de Bock w/ guests Dr Jörg Büscher & Prof Dr Petya Apostolova discuss the critical role of metabolism in cellular function, particularly in the context of hematology & cancer research.
All major podcast platforms 🎧 https://bit.ly/4kiYh5w 📺https://bit.ly/46XCQBY
Host Dr Charles de Bock w/ guests Dr Jörg Büscher & Prof Dr Petya Apostolova discuss the critical role of metabolism in cellular function, particularly in the context of hematology & cancer research.
All major podcast platforms 🎧 https://bit.ly/4kiYh5w 📺https://bit.ly/46XCQBY